StocksMedium•13 November 2026•
1 min read
GSK Receives Positive EU Recommendation for Newborn Meningococcal Vaccine
Key Facts
1GSK received a positive recommendation in the European Union for the use of its meningococcal disease vaccine in newborns.
GSK received a positive recommendation in the European Union for the use of its meningococcal disease vaccine in newborns. Benzinga reported that the recommendation follows a regulatory review of the vaccine's safety and efficacy for the newborn demographic in the European market. This move is expected to expand the potential market reach for the product line.
GSK closed at $50.64 on November 12, 2026, with the stock reaching a day high of $51.07 and a low of $50.45. This regulatory milestone coincides with broader economic data from the European Union, where the balance of trade was reported at -10.3 and annual employment growth held at 0.4% on November 13, 2026.